AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 102 min read$LLY

Hakim Anat sold $6.0M of LLY (indirect holdings)

Hakim Anat (EVP, GC & Secretary) sold 5,000 indirectly-held shares of ELI LILLY & Co (LLY) at $1190.00 ($5.95M total) on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hakim Anat
Published Aug 10, 2026, 8:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LLY
Neutral
medium confidence
Mentioned
$LLY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LLYNeutralLow
01

Why it matters

The newest disclosed fact is the specific 10b5-1 sale size, price, and post-transaction holdings for Hakim Anat.

02

Market read

This provides incremental transparency on insider activity but does not introduce new operational or financial guidance.

03

What to watch

Because the sale is indirect and pre-arranged, traders should avoid over-weighting it versus upcoming LLY-specific catalysts (earnings, guidance, trial/regulatory updates).

Relevance 5/10Novelty 4/10Timing: filed 2026-08-10 after-hours; transaction dated 2026-08-07

Background

The article is an SEC Form 4 insider transaction disclosure for Eli Lilly & Co, reported via EDGAR.

Company-level read

Ticker impact

$LLYNeutralMedium confidence
Context

Hakim Anat, LLY EVP, GC and Secretary, sold 5,000 shares at $1,190/share under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any effect is likely limited to short-term sentiment around the filing.

Evidence & confidence

The filing is a Form 4 insider transaction with an explicit pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary sales.

Market effects

Sector

No direct sector read-through; this is company-specific insider transaction data.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Insider sales can still reflect personal liquidity needs rather than bearish views, especially when tied to a 10b5-1 schedule.

Key entities

  • issuer
    LLY

    Eli Lilly & Co, the company whose insider transaction is disclosed.

  • insider
    Hakim Anat

    EVP, GC and Secretary at LLY, reported an open-market sale under a pre-arranged 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LLY insider trading history →

Related articles

NOV 3
$LLYHighAI 9/10

Forget Nvidia: Eli Lilly Will Become “the Most Valuable Company in the World,” Says Macro Investor

Eli Lilly (LLY) hit a record high, raising its 2026 revenue forecast to $91-$92B, lifting its market value to $1.1T. Macro investor Jordi Visser predicts Lilly will become the world's most valuable company due to steady healthcare spending and AI investment. Analysts expect Nvidia's (NVDA) earnings per share to quadruple in three years, making Lilly's potential surpass a significant challenge.

finance.yahoo.com2 min
NOV 3
$LLYHighAI 9/10

Eli Lilly Just Gained 22% in a Month: Take Profits, or Buy More?

Eli Lilly (LLY) stock rose 22% in October, driven by strong Q3 earnings, higher revenue guidance, and positive clinical trial results for retatrutide. Revenue increased 39% to $24.4B, with Mounjaro and Zepbound contributing significantly. Lilly raised 2026 revenue guidance to $91B-$92B. Goldman Sachs set a $1,413 price target. Novo Nordisk (NVO) faces competition from retatrutide, which outperformed Ozempic in a Phase 3 trial.

finance.yahoo.com2 min
NOV 3
$LLYMedAI 8/10

Micron, Samsung and SK hynix shares stumble, but this ETF rallies instead of chip stocks

ETFs focused on global pharmaceutical companies, particularly those in obesity treatment, saw strong returns amid tech and semiconductor stock declines. Eli Lilly reported Q3 revenue of $24.4B, up 38.6% YoY, driven by obesity drugs Mounjaro and Zepbound. Novo Nordisk and other Big Pharma stocks also rose, benefiting from defensive characteristics and upcoming clinical trial announcements.

mt.co.kr2 min
NOV 3
$LLYHighAI 9/10

Eli Lilly Posts Strong Quarterly Results and Hits Record High Stock Price

Eli Lilly (LLY) reported Q3 revenue of $24.4B, up 39% YoY, driven by GLP-1 drugs Mounjaro and Zepbound. The company raised full-year revenue guidance to $91B-$92B but slightly lowered EPS guidance to $35-$36. Despite strong growth, valuation concerns arise as the stock trades at 45x earnings, with market expectations already priced in.

nai500.com2 min